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Abstract
Background: The association between high risk human papillomaviruses (HPV) and cervical cancer has been firmly
established. HPV genome is present in nearly all cases of cervical cancer and detection of viral DNA could therefore
be used as a surrogate marker of micrometastasis in peri-tumor tissues and lymph nodes.
Methods: We analyzed primary cervical carcinomas, peri-tumor biopsies and pelvic lymph nodes in 20 women with
invasive cancer (FIGO stage I-II) who underwent radical pelvic surgery and lymphadenectomy. HPV DNA was
searched by broad spectrum PCR in 142 DNA samples extracted from paraffin embedded tissues. Viral genotypes
were identified by direct sequencing analysis.
Results: HPV DNA sequences were identified in all available primary cervical tumors (n = 15). The most common
genotype was HPV16 (60 %), followed by HPV18 (20 %), HPV35 (7 %), HPV45 (7 %) and HPV66 (7 %). Seven out of
20 (35 %) women had metastatic spread in peri-tumor tissues and/or lymph nodes, as determined by histology.
HPV DNA was detected in all histological positive samples as well as in 16 and 25 % of histological negative
peri-tumor tissues and lymph nodes, respectively. Three out of 20 (15 %) women without histological evidence of
metastatic spread had HPV-positive lymph nodes. HPV genotype was found always concordant between primary
tumor and metastatic lesions. The remaining 10 women (50 %) were histology and HPV-negative in all peri-tumor
biopsies and lymph nodes analyzed.
Conclusions: Evaluation of HPV DNA in peri-tumor tissues as well as pelvic lymph nodes could be a sensitive
marker to identify micrometastasis or isolated tumor cells and to monitor the risk of disease recurrence in women
with cervical cancer.
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Background
Cervical cancer is one of the most common tumors in
women with 528,000 new cases and 266,000 deaths world-
wide in 2012 [1]. The most frequent histological types are
squamous cell carcinoma and adenocarcinoma, represent-
ing 85 % and 10–15 % of all cervical cancers, respectively.
Nearly all cases of cervical squamous cell carcinoma
and adenocarcinoma are attributable to persistent infec-
tion with one of 12 high risk human papillomavirus
(HPV) genotypes, namely HPV16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58 and 59 [2, 3]. HPV-related carcinogenesis
is a long-term multistep process characterized by consti-
tutive expression of early viral genes E6 and E7, which
inactivate p53 and pRb oncosuppressors, respectively,
causing deregulation of several cellular pathways and
genomic instability [4].
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Specifically, the E6 protein of high risk HPVs has
shown to target p53 for fast proteasome-mediated deg-
radation causing abrogation of cell growth-arrest and
apoptosis [5, 6]. The E7 protein is able to bind and in-
activate pRb with a consequent increase in free E2F,
leading to both an increase in cyclin-dependent kinase
inhibitor p16 and abnormal cell proliferation [7–9].
A crucial event in cervical carcinogenesis is represented
by the integration of HPV genome into human chromo-
somes [10, 11]. DNA replication of HPV integrants has
been shown to cause multiple genetic alterations such as
formation of viral-host DNA concatemers, disruption of
chromosomal regions and amplification of HPV E6 and
E7 genes [12]. Viral sequences have been found frequently
inserted in some hot spots such as 3q28, 8q24.21 and
13q22 loci [13], involving transcriptionally active regions
[14], and preferentially within (34 %) or adjacent to fragile
sites (32 %) [14–16]. The most frequently affected genes
in either cervical intraepithelial neoplasia (CIN) or cancers
are POU5F1B (9.7 %), FHIT (8.7 %), KLF12 (7.8 %), KLF5
(6.8 %), LRP1B (5.8 %), HMGA2 (7.8 %), and SEMA3D
(4.9 %), supporting their oncogenic role in the clonal se-
lection and outgrowth of neoplastic cells in the early
stages of cervical carcinogenesis [17].
Standard treatment of cervical cancer is radical hyster-
ectomy, bilateral adnexectomy and systematic pelvic
lymph nodes removal [18, 19]. The histological type,
tumor size, depth of invasion, lymphovascular space in-
vasion, paracervical involvement and lymph nodal status
represent the most important parameters for prognosis
and choice of therapy [18, 20].
The metastatic spread of cervical carcinoma to pelvic
lymph-nodes has been found in 0–29.3 % of women
with early stages cervical cancer (FIGO IA1–IB1) and in
12–61.8 % of women with locally advanced disease
(FIGO IB2–IIB) [21, 22]. Nonetheless, a recurrence rate
of 10–15 % has been reported in patients with non-
metastatic lymph nodes, probably due to histologically
undetectable micrometastases or single tumor cells in
the lymphatic system [21, 22]. Strander et al. showed
that the long term risk of cancer among Swedish women
treated for cervical intraepithelial neoplasia grade 3
(CIN3) was 2.5 fold higher for the development of cer-
vical and vaginal carcinoma, compared with the general
female population [23]. The risk of metachronous genital
cancer lesions was higher in women treated over the age
of 50 and persisted for more than 25 years after the ini-
tial treatment [23].
Vinokurova et al. [24] analyzed the HPV integration
sites in multiple vaginal or vulvar metachronous lesions
arising in women previously treated (up to 10 years be-
fore) for high grade cervical lesions or carcinomas, with
resection margins reported to be disease free, and identi-
fied the same HPV integration sites in the primary as
well in metachronous lesions from the same patient.
These data support the hypothesis that vulvar and
vaginal lesions were likely derived from locally dissemi-
nated dormant neoplastic cells, not detectable by histo-
logical analysis, raising the need of detecting HPV DNA
by ultrasensitive molecular techniques in pelvic lymph
nodes and peri-tumor tissues [25].
The aim of this study was to analyze the HPV DNA se-
quences in cervical carcinoma biopsies, peri-tumor tissues
and pelvic lymph nodes to assess the sensitivity of molecu-
lar PCR method in identifying early metastasis or isolated
cancer cells compared to histology.
Methods
Patients and tissue samples
One hundred forty-two formalin-fixed and paraffin-
embedded biopsies from 20 patients referred to the
Gynecology Unit at the National Cancer Institute Fond
Pascale were included in the study. All enrolled patients
underwent surgical treatment for the removal of primary
tumor, adjacent tissues biopsies and pelvic lymph nodes
and histology of all samples was determined. All patients
with locally advanced cervical cancer (stages IB2 or worse)
received standard neo-adjuvant chemotherapy before sur-
gery. To perform molecular analysis, four 10-μm thick
sections from each paraffin block were obtained in separ-
ate sterile Eppendorf tubes for PCR analysis and two sec-
tions for hematoxylin–eosin staining. Slides immediately
adjacent to the tissue sections used for viral DNA analysis
were reviewed by the pathologist to verify the presence of
neoplastic tissue. Histological subtypes were determined
in accordance to Young et al. [26] and to the Bethesda
2001 system [27]. Tissues were graded as adenocarcinoma
(endometrioid, clear cell and serous types, n = 4), and
invasive squamous cell carcinoma (n = 16). This study was
approved by the Institutional Scientific Board and by the
Ethical Committee of the Istituto Nazionale Tumori “Fond
Pascale”, and is in accordance with the principles of the
Declaration of Helsinki.
DNA isolation
Genomic DNA was extracted according to published
procedures [28]. In particular tissue samples were
digested over night at 56 °C with Proteinase K (200 μg
per ml) in 100 μl of lysis buffer (50 mM Tris-HCl
pH 8.5, 1 mM EDTA, 0.5 % Tween20), followed by DNA
purification by phenol and phenol-chloroform-isoamyl
alcohol (25:24:1) extraction and ethanol precipitation in
0.3 M sodium acetate (pH 4.6).
PCR amplification
The concentration of all manually extracted DNA samples
was evaluated by spectrophotometry (NanoDrop™ 2000).
The quality of nucleic acid was determined by PCR
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amplification of a 150 bp fragment within the exon 7 of
TP53 gene [29]. HPV detection was carried out by nested
PCR with MY09/MY11 primer pairs [30] for the outer re-
action and MGP primer system for the inner reaction in
50 μl reaction mixture containing 5 μl of outer reaction,
as described previously [31]. This PCR system was evalu-
ated for its sensitivity and specificity for individual HPV
types by using a proficiency panel of HPV plasmids in ser-
ial dilutions, both alone and in combination, obtained in
the context of the 4th WHO HPV LabNet Proficiency
Study for Evaluating HPV DNA Typing Methods (2010).
The system was evaluated as proficient for detection of
HPV 16, 18, 31, 33, 35, 39, 45, 52, 56, 58, 59, 66 and 68b,
being able to detect 50 genome equivalents (GE)/5 μl of
HPV 16 and HPV 18 DNA, and 500 GE/5 μl of the other
HPV types with a specificity above 97 % [32]. A reaction
mixture without template DNA, as negative control, was
included in every set of five clinical specimens for each
PCR run.
The amplification products were subjected to electro-
phoresis on a 7 % polyacrylamide gel followed by staining
with ethidium bromide. The image was scanned with the
system image capture Gel Doc (Bio-Rad). HPV genotypes
were identified by direct automated DNA sequencing ana-
lysis of MGP amplified products using both the forward
GP5+ and reverse GP6+ oligoprimers [33] at Eurofins La-
boratories (Milan). HPV type identification was performed
by alignments of HPV sequences with those present in the
GenBank database using the BLASTn software (http://
www.ncbi.nlm.nih.gov/blast/html).
Statistical analyses
The data were analyzed with Epi Info 6 Statistical Ana-
lysis System Software (Version 6.04b, 1997, Centers for
Disease Control and Prevention, USA). Unpaired t test
was used for comparisons of continuous variables (i.e.
age); Yates-corrected χ2 test and, where appropriate,
two-sided Fisher’s exact test were used for comparison
of categorical data. Differences were considered to be
statistically significant when P values were less than
0.05.
Results
The study included 20 women with a mean age at diag-
nosis of 48.3 (±11.84) years. According to FIGO staging
the study included four IA (20 %), ten IB (50 %), three
IIA (15 %), two IIB (10 %) and one IIIB (5 %) stage pa-
tients (Table 1). Sixteen (80 %) cases were diagnosed as
squamous cell carcinoma (SCC) and four (20 %) as
adenocarcinoma (AC) of the cervix.
All tissue samples obtained from each woman were
grouped in 1) primary tumors, 2) peri-tumor tissues and 3)
pelvic lymph node samples, each consisting of a lymph
node station comprising between 2 and 25 lymph nodes in
one or more inclusions. In total 142 tissue samples were
analyzed of which 15 primary tumors, 54 peri-tumor tissues
and 73 lymph node inclusions for a total of 304 lymph
nodes. Samples from primary tumor biopsies were not
available in five patients.
Seven out of 20 (35 %) women had metastatic spread
in peri-tumor tissues and/or lymph nodes, as determined
by histology. In particular, three patients (43 %) had
pelvic lymph nodes metastases, three (43 %) peri-tumor
invasion and one patient (14 %) had both peri-tumor
and pelvic lymph nodes metastases.
The distribution of viral genotypes is shown in Table 2.
Overall, HPV DNA sequences were detected in 63 out of
142 (44.4 %) samples. The most common HPV genotype
was HPV16 (51/63, 81 %), followed by HPV18 (4/63,
6.3 %), HPV45 (4/63, 6.3 %), HPV35 (2/63, 3.2 %) and
HPV66 (2/63, 3.2 %). All available primary tumor samples
were positive for HPV DNA sequences. The most com-
mon genotype was HPV16 (9/15, 60 %), followed by
HPV18 (3/15, 20 %), HPV35 (1/15, 7 %), HPV45 (1/15,
7 %) and HPV66 (1/15, 7 %). All histological positive peri-






Mean age (±SD) 48. 3 (±11,84) 45.86 (±12.9)
≤ 45 10 4 (57.2 %)
> 45 10 3 (42.8 %)
FIGO Stage
I A 4 (20 %) 0 -
I B 10 (50 %) 4 (57.1 %)
II A 3 (15 %) 1 (14.3 %)
II B 2 (10 %) 1 (14.3 %)
III B 1 (5 %) 1 (14.3 %)
Histopathology
Squamous cell carcinoma (SCC) 16 (80 %) 6 (85.8 %)
Adenocarcinoma (AC) 4 (20 %) 1 (14.2 %)
Grading
Well differenziated (G1) 2 (10 %) 1 (14.2 %)
Moderately differentiated (G2) 6 (30 %) 1 (14.2 %)
Poorly differentiated (G3) 12 (60 %) 5 (71.6 %)
Volume of primary lesion
< 2 cm 4 (20 %) 0 -
2-4 cm 3 (15 %) 2 (28.6 %)
> 4 2 (10 %) 2 (28.6 %)
Tumor Invasion
Peri-tumor tissues 3 (15 %) 3 (42.9 %)
Lymph nodes 3 (15 %) 3 (42.9 %)
Peri-tumor + Lymph nodes 1 (5 %) 1 (14.2 %)
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tumor tissues (n = 23) and lymph nodes (n = 3 groups)
were positive for HPV DNA sequences. Moreover, viral
DNA was detected in 5 out of 31 peri-tumor tissues
and in 17 out of 68 lymph nodes groups (comprising a
total of 182 lymph nodes) which were histological
negative for micrometastasis (Tables 2 and 3). There
was no statistically significant difference in the fre-
quency of HPV positive lymph nodes (p = 0.94) or peri-
tumor tissues (p = 0.63) according to FIGO stages.
However, bias could have occurred due to the small
number of patients in some FIGO groups.
During a 24 months follow-up period one patient died
and 5 experienced disease recurrence: two patients
(SCC-04 and AC-19, positive for HPV16 and 18, respect-
ively) had loco-regional recurrence, two (SCC-07 and
SCC-39, positive for HPV35 and 16, respectively) were di-
agnosed with distant metastasis outside the pelvis and one
patient (SCC-12, positive HPV16) was diagnosed with
both loco-regional and distant metastases (Table 2). Two
patients (SCC-22 and SCC-41, positive for HPV45 and 66,
respectively) with histological negative/HPV-positive peri-
tumor and/or lymph nodes samples had no recurrence
during the follow up. Information on disease recurrence
was not available for the remaining 6 patients.
All HPV genotypes identified in peri-tumor samples
and lymph nodes were concordant with that identified
in the corresponding primary tumor. Moreover in one
case the HPV16 DNA sequences amplified in the pri-
mary tumor (SCC-45) and corresponding lymph nodes
(LN45), both contained two nucleotide changes (nt 6695
[A > C] and 6721 [G > A]) distinctive of Asian-American
variants, supporting the clonality of tumor cells (Fig. 1).
Discussion
Lymph node status in women with cervical cancer is the
most important parameter for predicting outcome of
Table 2 Presence of HPV DNA in histological positive and negative peri-tumor tissues and lymph nodes from cervical cancer patients
Cases Histol Grade FIGO Stage Metast. Peri-tumor (%) Metastatic LN (%)a HPV-pos Peri-tumor (%) HPV-pos LN (%) HPVb Recurrencec
SCC-04 SCC 3 IB 3/6 (50) 0/4 - 4/6 (66.6) 2/4 (50) HPV16 Pelvic
SCC-05 SCC 2 IA 0/2 - 0/1 - 0/2 - 0/1 - HPV18 No
SCC-07 SCC 3 IIIB 1/2 (50) 0 - 1/2 (50) 0 - HPV35 Lung
SCC-09 SCC 3 IA 0/4 - 0/1 - 0/4 - 0/1 - n/a No
SCC-12 SCC 2 IIA 0 - 0/1 - 0 - 0/1 - HPV16 Pelvic/Lung
SCC-20 SCC 3 IA 0/3 - 0/2 - 0/3 - 0/2 - n/a No
SCC-22 SCC 2 IB 0/2 - 0/3 - 1/2 (50) 2/3 (66.6) HPV45 No
SCC-24 SCC 1 IB 0/2 - 0/6 - 1/2 (50) 5/6 (83.3) HPV16 n/a
SCC-39 SCC 3 IIB 0 - 1/4 (25) 0 - 3/4 (75) HPV16 Lung
SCC-41 SCC 3 IB 0/3 - 2/3 (66.6) 1/3 (33.3) 0/3 - HPV66 No
SCC-42 SCC 2 IA 0 - 0/3 - 0 - 0/3 - n/a No
SCC-43 SCC 3 IB 0 - 0/9 - 0 - 0/9 - n/a No
SCC-44 SCC 3 IB 8/9 (88.8) 0/6 - 8/9 (88.8) 6/6 (100) HPV16 n/a
SCC-45 SCC 1 IB 11/11 (100) 1/10 (10) 11/11 (100) 1/10 (10) HPV16 n/a
SCC-46 SCC 3 IB 0 - 0/8 - 0 - 0/8 - HPV16 n/a
SCC-47 SCC 3 IIB 0 - 0/2 - 0 - 0/2 - HPV16 Dead
AC-10 AC 3 IB 0/5 - 0/3 - 1/5 (20) 0/3 - HPV16 n/a
AC-11 AC 2 IIA 0/1 - 1/4 (25) 0/1 - 1/4 (25) HPV18 n/a
AC-18 AC 3 IB 0/4 - 0/2 - 0/4 - 0/2 - n/a No
AC-19 AC 2 IIA 0 - 0/1 - 0 - 0/1 - HPV18 Pelvic
a Each lymph node inclusion comprises 2–25 lymph nodes for a total of 304 lymph nodes
b n/a - primary tumor was not available
c n/a - Information on disease recurrence was not available; No- no disease recurrence, Local - loco regional recurrence, Distant - metastasis outside the pelvis
Table 3 Comparison between histology and PCR results
HPV PCR pos (%) HPV PCR neg (%) P valuea
Primary tumor
Histology pos (%) 15 (75) 0
Peri-tumor tissues
Histology pos (%) 23 (42.6) 0
Histology neg (%) 5 (9.3) 26 (48.1) <0.0001
Lymph-nodes
Histology pos (%) 3 (4.1) 2 (2.7)
Histology neg (%) 17 (23.3) 51 (69.9) 0.2403
a Yates-correction χ2 test
Tortora et al. Infectious Agents and Cancer  (2016) 11:22 Page 4 of 7
disease and for planning post-surgery adjuvant therapy
[18]. However, a significant proportion of women,
treated for early stage cervical cancer and without nodal
metastasis, develop local or distant disease up to decades
after successful treatment of primary lesions [23].
Balamurugan et al. analyzed the Epidemiology and End
Results (SEER) cancer data, collected during the period
1992–2004, and observed a higher risk of in situ and in-
vasive cancers of the vagina (standardized incidence ra-
tios, SIRs of 53.8 and SIRs of 29.9, respectively) and
vulva (SIRs of 6.6 and 5.7 for invasive cancer, respect-
ively) among cervical cancer survivors [34].
The analysis of HPV DNA, generally integrated within
the genome of the host cancer cells, could represent a
sensitive marker of micrometastases and single tumor
cell spread in pathologically-negative peri-tumor tissues
and lymph nodes [25]. Since the first report by Lancaster
et al. [35] on the utility of HPV DNA detection in lymph
nodes as surrogate marker of cervical cancer metastasis,
several retrospective and prospective studies were con-
ducted with the aim to validate the clinical usefulness of
this analysis, often with divergent results [25].
In the current retrospective study, we have identified
HPV sequences in all histological positive samples as well
as in 16 and 25 % of histological negative peri-tumor tissues
and lymph nodes, respectively. Among the seven women
with histological evidence of metastatic spread the number
of HPV positive lymph nodes and/or peri-tumor tissues
was much higher compared to histological analysis. Three
out of 20 (15 %) women had at least an HPV-positive
lymph node sample without histological evidence of meta-
static spread. Our results are in agreement with several
published studies. In particular, Noventa et al. [25] in the
systematic review including 15 studies on the histology and
HPV detection in lymph nodes among 1333 patients with
early stage cervical cancer, showed that HPV DNA was
present in 75 % of cases with at least one lymph node me-
tastasis (488 women) and in 39 % of cases without meta-
static involvement (913 women). Higher rates of HPV
positivity have been reported by Slama et al. [36] which,
based on their work on fresh tissues, found viral genomes
in 66.6 % of histological negative lymph nodes from
patients without metastatic involvement.
Several studies showed that presence of HPV-DNA in
lymph nodes is associated with increased risk of disease
recurrence and reduced overall survival [37–39]. Others
reported no significant differences in recurrence or over-
all survival between patients with positive and negative
HPV-DNA lymph nodal status independently from the
histology [40, 41]. Lukaszuk et al. [42] conducted the
first prospective study on frozen fresh-tissues of cervical
lesions and pelvic lymph nodes and demonstrated that
viral DNA in lymph nodes was an independent onco-
logical risk factor, correlating with survival and mortality
rate. More recently, Durst et al. [43] evaluated the ex-
pression of HPV E6/E7 mRNA as a molecular marker
Fig. 1 DNA sequence electropherograms showing HPV 16 Asian–American nucleotide signatures in L1 region at nucleotide position 6695 (A > C)
and 6721 (G > A) in the primary tumor (SCC45) and metastatic lymph node (Ly45)
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for the detection of tumor cells in fresh biopsies of
histological negative sentinel lymph nodes and showed
that recurrence-free survival was significantly longer for
patients with HPV mRNA negative sentinel lymph nodes
(log rank p = 0.002).
In our study the most representative viral genotypes in
all HPV positive tissues were HPV16 (81 %), followed by
HPV18 (6.3 %), HPV45 (6.3 %), HPV35 (3.2 %) and
HPV66 (3.2 %). The HPV genotype was always concord-
ant between primary tumor and metastatic/non meta-
static HPV-positive lesions from the same patient.
Accordingly, Landro et al. [41] reported a high preva-
lence of HPV16 and HPV18 in primary lesions (84 and
27 % positive, respectively) and lymph nodes (46 and
20 %, respectively). In their study the correspondence of
viral genome between primary lesion and lymph nodes
was 73 %, while in 13.5 % of cases the viral sequences
were not concordant and in 13.5 % the HPV DNA was
not detected [41]. In fact, it is expected that in some
cases the HPV positivity is due to the ability of immune-
competent phagocytes to transport the HPV-positive
cells and/or viral particles from the primary tumor to
lymph nodes. Landro et al. [41], observed that in
metastases-free lymph nodes the HPV sequences were
evident by PCR and in situ hybridization in nuclei and/
or cytoplasm of lymphocytes from germinal centers or
cortical areas, in endothelial cells, in macrophages and
in stromal cells. In metastatic lymph nodes the HPV
DNA was detected in all the previous mentioned cells
and also in squamous invasive cells.
The main limitations of our study include its retro-
spective design, the inability to evaluate long term dis-
ease recurrence of these women, and the small number
of patients, although the number of samples analyzed
for each patient was relatively high.
Conclusions
In conclusion, our data suggest that the analysis of HPV
sequences is more sensitive compared to histological
analysis. The clinical implications of HPV DNA se-
quences in peri-tumor tissues and lymph nodes and the
benefit for the patients with respect to prediction of dis-
ease recurrence and therapy options will have to be ad-
dressed in further prospective studies.
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